Ibrutinib-Rituximab Combo Beats Chemoimmunotherapy for CLL
Progression-free, overall survival improved in the ibrutinib-rituximab group at three years.
Diagnosis & Disease Information
Ibrutinib Compared With Chemotherapy in Treatment-Naive CLL
Ibrutinib monotherapy may reduce the need for chemotherapy for some treatment-naive patients with chronic CLL, research indicates.
Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib
[Cancer Management and Research] A review of marginal zone lymphomas, a common and varied group of hematologic malignancies, and their treatment, with a focus on the Bruton’s tyrosine kinase ibrutinib.
Managing Adverse Effects From Oral Kinase Inhibitors in Patients With Hematologic Cancers
Ibrutinib, idelalisib, ponatinib, and ruxolitinib are each associated with a variety of potential adverse effects and oncology nurses must be aware of these to successfully monitor for them.
What Is The Optimal Sequencing of Novel Agents for CLL?
Ibrutinib appears to be superior first kinase inhibitor for individuals with chronic lymphocytic leukemia, according to a recent real-world study.
Reasons behind ibrutinib discontinuation among patients with chronic lymphocytic leukemia
A tenth of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase inhibitor ibrutinib because of disease progression during clinical trials, according to a study.
Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia
About 10% of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib discontinued their therapy due to disease progression during clinical studies.
Rational drug combinations may overcome ibrutinib resistance
Genomic analyses of tumor and healthy tissue from patients with mantle cell lymphomas provided explanations for two types of resistance to ibrutinib and suggested ways to overcome them.
Resistance to ibrutinib in chronic lymphocytic leukemia explained
A new study has discovered how resistance develops in patients taking ibrutinib, a new and highly effective drug for the treatment of chronic lymphocytic leukemia.
FDA: ibrutinib approval to include CLL
Approval of ibrutinib (Imbruvica) has been expanded to include people with chronic lymphocytic leukemia.
- Loading...
Loading...
Loading... 
Loading...